首页/数据集/miR-134/487b/655 Cluster regulates TGF-M-NM-2-induced epithelial-mesenchymal transition and drug resistance to Gefitinib by targeting MAGI2 in lung adenocarcinoma cells.

miR-134/487b/655 Cluster regulates TGF-M-NM-2-induced epithelial-mesenchymal transition and drug resistance to Gefitinib by targeting MAGI2 in lung adenocarcinoma cells.

ChEBI2013-10-30 更新2026-07-21 收录

化疗耐药机制

上皮-间质转化

数据链接：

https://www.ebi.ac.uk/biostudies/ArrayExpress/studies/E-GEOD-51828 数据链接链接失效反馈

官方服务：

资源简介：

miR-134/487b/655 Cluster regulates TGF-M-NM-2-induced epithelial-mesenchymal transition and drug resistance to Gefitinib by targeting MAGI2 in lung adenocarcinoma cells.

应用场景：

创建时间：

2013-10-30

头颈部鳞状细胞癌基因

化疗耐药机制

In order to investigate the mechanisms underlying response and resistance towards treatment in HNSCC, we used low passage in vitro HNSCC cultures from two patients, namely SJG26 and SJG17. Both cultur

NIAID Data Ecosystem70

Analysis of epithelial and mesenchymal populations in tumor-derived cell lines by scRNA-seq

单细胞转录组学

上皮-间质转化

This experiment includes single cell transcriptome data for the epithelial and mesenchymal populations isolated from a pancreatic tumor induced in GEM mouse.

NIAID Data Ecosystem30

High-resolution Nanopore methylome-maps reveal random hyper-methylation at CpG-poor regions as driver of chemoresistance in leukemias.[RNA-Seq]

癌症表观遗传学

化疗耐药机制

Aberrant DNA-methylation at CpG dinucleotides is a hallmark of cancer and is associated with the emergence of resistance to anti-cancer treatment, though molecular mechanisms and biological signifi-

NIAID Data Ecosystem20

DataSheet2_Exogenous proline enhances susceptibility of NSCLC to cisplatin via metabolic reprogramming and PLK1-mediated cell cycle arrest.xlsx

化疗耐药机制

代谢重编程

The occurrence of cisplatin resistance is still the main factor limiting the therapeutic effect of non-small cell lung cancer (NSCLC). It is urgent to elucidate the resistance mechanism and develop no

NIAID Data Ecosystem40

Unveiling alterations of epigenetic modifications and chromatin architecture leading to lipid metabolic reprogramming during the evolutionary trastuzumab adaptation of HER2-positive breast cancer [Cut & Tag]. Unveiling alterations of epigenetic modifications and chromatin architecture leading to lipid metabolic reprogramming during the evolutionary trastuzumab adaptation of HER2-positive breast cancer [Cut & Tag]

化疗耐药机制

表观遗传调控

Secondary trastuzumab resistance represents an evolutionary adaptation of HER2-positive breast cancer during anti-HER2 treatment. Most current studies have uncovered the alternations of HER2 and assoc

NIAID Data Ecosystem20

miR-134/487b/655 Cluster regulates TGF-M-NM-2-induced epithelial-mesenchymal transition and drug resistance to Gefitinib by targeting MAGI2 in lung adenocarcinoma cells.

资源简介：

相关数据集